Pediatria Polska

Abstract

1/2026 vol. 101
Case report

Treatment-related toxicities in acute lymphoblastic leukemia in a child with Marfan syndrome: a case report

  1. Department of Pediatric Oncology and Hematology, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland
  2. Student Scientific Club of Pediatric Oncology and Hematology, Jagiellonian University Medical College, Cracow, Poland
Pediatr Pol 2026; 101 (1): 95-104
Online publish date: 2026/03/27
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
Marfan syndrome (MFS) is a connective tissue disorder caused by mutations in the fibrillin-1 gene. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. The coexistence of MFS and ALL is rare and presents a unique clinical challenge. We report the case of an 8.5-year-old boy with MFS who developed precursor B-cell acute lymphoblastic leukemia with the ETV6-RUNX1 fusion gene. He achieved complete remission with initial chemotherapy. Two years later, he experienced a relapse involving the testes and central nervous system. Subsequent treatment led to severe complications. Whole exome sequencing revealed multiple pathogenic variants, including a CHEK2 mutation, potentially contributing to the malignancy and treatment-related toxicities. This case highlights the potential role of dysregulated transforming growth factor β signaling in MFS contributing to leukemogenesis. The patient’s severe complications and co-occurrence of MFS underscore the need for personalized therapeutic strategies and comprehensive, multidisciplinary care. Further research is essential to improve clinical outcomes.
Share
without publication fees
without publication fees